Wainwright says Viking’s VK2735 holds strong as competitor data raises eyebrows

H.C. Wainwright analyst Joseph Pantginis believes Viking Therapeutics’ (VKTX) VK2735 remains a standout among competitors after Eli Lilly’s (LLY) data was released today from its Phase 3 ATTAIN-1 trial. This study evaluated its once-daily small molecule GLP-1 receptor agonist, orforglipron, in adults with obesity, or overweight with a weight-related medical problem and without diabetes over 72 weeks. The firm notes investors did not react positively to the data, but notes positive sentiment for Viking stock can also be seen this morning. The dropout rate stands out to Wainwright, especially when comparing this to Viking’s oral VK2735 Phase 1 data that saw similar or better adverse-related discontinuation rates up to the highest dose of 100 mg over a 28-day period. The firm has a Buy rating on Viking’s shares with a price target of $102.